Gilead ties up with generic drugmakers for COVID-19 drug supply

0
2

Gilead Sciences said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir. The pacts allow the companies ? Jubilant Life Sciences, Cipla , Hetero Labs, Mylan NV and Ferozsons Laboratories ? to make and sell the drug in 127 countries.

NO COMMENTS